Dong-A, Green Cross likely immune to financial crisis

Published: 2011-11-15 06:57:00

Updated: 2011-11-15 06:57:00

Chances are looming larger that a majority of pharmaceutical firms, except for Dong-A Pharmaceutical and Green Cross Crop., will face a blow for their revenues as the government’s new drug pricing initiative could not only slash their sales and operating profits by 20 percent but push many margin...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK